131 related articles for article (PubMed ID: 36576813)
1. Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery.
Famularo S; Donadon M; Cipriani F; Fazio F; Ardito F; Iaria M; Perri P; Conci S; Dominioni T; Lai Q; La Barba G; Patauner S; Molfino S; Germani P; Zimmitti G; Pinotti E; Zanello M; Fumagalli L; Ferrari C; Romano M; Delvecchio A; Valsecchi MG; Antonucci A; Piscaglia F; Farinati F; Kawaguchi Y; Hasegawa K; Memeo R; Zanus G; Griseri G; Chiarelli M; Jovine E; Zago M; Abu Hilal M; Tarchi P; Baiocchi GL; Frena A; Ercolani G; Rossi M; Maestri M; Ruzzenente A; Grazi GL; Dalla Valle R; Romano F; Giuliante F; Ferrero A; Aldrighetti L; Bernasconi DP; Torzilli G;
JAMA Surg; 2023 Feb; 158(2):192-202. PubMed ID: 36576813
[TBL] [Abstract][Full Text] [Related]
2. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
3. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
[TBL] [Abstract][Full Text] [Related]
4. Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era.
Pfiffer TE; Seehofer D; Nicolaou A; Neuhaus R; Riess H; Trappe RU
Tumori; 2011; 97(4):436-41. PubMed ID: 21989430
[TBL] [Abstract][Full Text] [Related]
5. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
[TBL] [Abstract][Full Text] [Related]
7. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study.
Wang K; Liu G; Li J; Yan Z; Xia Y; Wan X; Ji Y; Lau WY; Wu M; Shen F
Eur J Surg Oncol; 2015 Feb; 41(2):236-42. PubMed ID: 25434327
[TBL] [Abstract][Full Text] [Related]
8. A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection.
Umeda Y; Matsuda H; Sadamori H; Matsukawa H; Yagi T; Fujiwara T
World J Surg; 2011 Jan; 35(1):170-7. PubMed ID: 20922387
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
Liu C; Sun L; Xu J; Zhao Y
World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
[TBL] [Abstract][Full Text] [Related]
10. Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis.
Chen S; Shi M; Shen L; Qi H; Wan W; Cao F; Xie L; Wu Y; Chen G; Mo J; Zhu G; Ye D; Zhang Y; Feng Z; Xu L; Fan W
Int J Hyperthermia; 2020; 37(1):384-391. PubMed ID: 32323585
[No Abstract] [Full Text] [Related]
11. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
[TBL] [Abstract][Full Text] [Related]
12. The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion.
Peng Z; Wu X; Li J; Pang H; Zhang Y; Lin M; Wang Z; Xiao H; Li B; Chen M; Feng S; Kuang M; Chen S
Int J Hyperthermia; 2022; 39(1):688-696. PubMed ID: 35469522
[TBL] [Abstract][Full Text] [Related]
13. Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma.
Feng X; Feng GY; Tao J; Ao YP; Wu XH; Qi SG; Shi ZR
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10505-10518. PubMed ID: 37284841
[TBL] [Abstract][Full Text] [Related]
14. Ischemic Cholangiopathy Following Transcatheter Arterial Chemoembolization for Recurrent Hepatocellular Carcinoma After Hepatectomy: an Underestimated and Devastating Complication.
Nakada S; Allard MA; Lewin M; Awad S; Dahbi N; Nitta H; Cunha AS; Castaing D; Vibert E; Cherqui D; Miyazaki M; Ohtsuka M; Adam R
J Gastrointest Surg; 2020 Nov; 24(11):2517-2525. PubMed ID: 31754989
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China.
Wu Z; Cui L; Qian J; Luo L; Tu S; Cheng F; Yuan L; Zhang W; Lin W; Tang H; Li X; Li H; Zhang Y; Zhu J; Li Y; Xiong Y; Hu Z; Peng P; He Y; Liu L; He K; Shen W
BMC Cancer; 2023 Apr; 23(1):325. PubMed ID: 37029339
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
Kuo MJ; Mo LR; Chen CL
BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
[TBL] [Abstract][Full Text] [Related]
20. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
